Extended Data Fig. 6: Evidence for independent primary prostate tumors in three patients.
See Supplementary Fig. 5 for the four other patients with multiple independent cancers. The prostate schematics show the approximate location of profiled prostate biopsy (PB) cores and radical prostatectomy (RP) regions (no map was available for ID38). Estimated extent of tumor involvement (as determined by histopathological review) is shown, and independent tumors (labeled A, B, and C) are indicated. For select representative (‘model’) samples from each independent tumor, the highest observed International Society of Urological Pathology (ISUP) grade and key genomic alterations are shown. Different patterns of copy number alterations in genes (middle) from targeted sequencing for the model samples; coloring indicates deep deletion (dark blue), shallow deletion (light blue), copy-neutral (black), copy-gain (red) and amplification (dark red). Scatterplots (right) and Pearson correlation of all mutations detected via whole-exome sequencing in select sample pairs depict no overlap between independent tumors. Del: deletion, Mut: mutation. ADT: androgen-deprivation therapy, TF: tumor fraction, UCC: urothelial carcinoma, VAF: variant allele fraction.
